Ambrisentan
| CAS No. | 177036-94-1 | Cat. No. | BCP22426 |
| Name | Ambrisentan | ||
| Synonyms | BSF-208075; BSF208075; BSF 208075; LU-208075; LU208075; LU 208075; | ||
| Formula | C22H22N2O4 | M. Wt | 378.43 |
| Description | Ambrisentan, also known as BSF-208075 and LU-208075, is a drug indicated for use in the treatment of pulmonary hypertension. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan significantly improved exercise capacity (6-minute walk distance) compared with placebo in two double-blind, multicenter trials (ARIES-1 and ARIES-2). Ambrisentan was approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency, and designated an orphan drug, for the treatment of pulmonary hypertension. | ||
| Pathways | GPCR/G Protein | ||
| Targets | Endothelin Receptor | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.